The clinical efficacy of compound Danshen injection on acute cerebral infarction and on the changes in the CRP, D-dimer, and IL-6 levels

Fengming Bian; Shijin Kang; Honghai Cui; Fang Wang; Tianwei Luan

The clinical efficacy of compound Danshen injection on acute cerebral infarction and on the changes in the CRP, D-dimer, and IL-6 levels

Am J Transl Res. 2021 Jul 15;13(7):8126-8133. eCollection 2021.

Authors

Fengming Bian¹, Shijin Kang², Honghai Cui³, Fang Wang¹, Tianwei Luan¹

Affiliations

¹ Department of Neurology, The Fifth Hospital in Harbin Harbin, Heilongjiang Province, China.
² Department of Neurology, Mishan People's Hospital Mishan, Heilongjiang Province, China.
³ The Second Ward, Department of General Internal Medicine, Daoli District People's Hospital Harbin, Heilongjiang Province, China.

PMID: 34377296
PMCID: PMC8340209

Abstract

Objective: To study the clinical curative effect of compound Danshen injection on acute cerebral infarction (ACI) patients and its impact on the CRP, D-dimer, and IL-6 levels.

Methods: 116 patients with ACI admitted to our hospital were randomly placed in an observation group (n=58) or a control group (n=58). The control group received rosuvastatin tablets (10 mg/time, qd) in addition to the standard treatment. The observation group received compound Danshen injection in addition to the standard treatment. The treatment continued for 21 days. The clinical treatment efficacy, the CRP, D-dimer, and IL-6 levels, the NIHSS scores (to evaluate the degree of neurological impairment), the Fugl-Meyer scores (to access patients' motor function), the ADL scores, the sleep quality (the PSQI and AIS scores), and the complication incidence rates were compared between the two groups.

Results: After the treatment, the effective rate in the observation group (89.66%) was significantly higher than it was in the control group (74.14%) (P<0.05). After the treatment, the serum CRP, D-dimer, and IL-6 levels in the two groups were lower than they were before the treatment, and the levels were lower in the observation group than they were in the control group (all P<0.05). After the treatment, the NIHSS scores in the observation group were lower than they were in the control group, and the Fugl-Meyer and ADL scores were higher than they were in the control group (all P<0.05). Compared with the control group, the PSQI and AIS scores in the observation group were lower than they were in the control group after the treatment (P<0.05). The severe diarrhea, bedsore, urinary tract infection, liver and kidney function injury, skin allergic reactions and other total adverse reaction incidence rates in the observation group were lower than they were in the control group.

Conclusion: Rosuvastatin combined with compound Danshen injection is effective in ACI treatment. It is able to effectively improve the clinical symptoms, reduce the incidence of complications, improve the recovery of the IL-6, CRP, and D-dimer levels and enhance patients' sleep quality.

Keywords: CRP; Compound Danshen injection; D-dimer; IL-6; acute cerebral infarction; clinical efficacy.